Nuvation Bio Statistics
Share Statistics
Nuvation Bio has 336.57M shares outstanding. The number of shares has increased by 53.15% in one year.
| Shares Outstanding | 336.57M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 35.04% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 228.20M |
| Failed to Deliver (FTD) Shares | 248 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 11.32M, so 3.36% of the outstanding shares have been sold short.
| Short Interest | 11.32M |
| Short % of Shares Out | 3.36% |
| Short % of Float | 4.96% |
| Short Ratio (days to cover) | 7.28 |
Valuation Ratios
The PE ratio is -4.36 and the forward PE ratio is -4.65.
| PE Ratio | -4.36 |
| Forward PE | -4.65 |
| PS Ratio | 0 |
| Forward PS | 1335.7 |
| PB Ratio | 0.55 |
| P/FCF Ratio | -4.86 |
| PEG Ratio | n/a |
Enterprise Valuation
Nuvation Bio Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 44.11, with a Debt / Equity ratio of 0.
| Current Ratio | 44.11 |
| Quick Ratio | 44.11 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.32 |
| Cash Flow / Debt | -34.48 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.13% and return on capital (ROIC) is -16.39%.
| Return on Equity (ROE) | -0.13% |
| Return on Assets (ROA) | -0.12% |
| Return on Capital (ROIC) | -16.39% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -373.41K |
| Employee Count | 203 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 85.82% in the last 52 weeks. The beta is 1.36, so Nuvation Bio 's price volatility has been higher than the market average.
| Beta | 1.36 |
| 52-Week Price Change | 85.82% |
| 50-Day Moving Average | 2.56 |
| 200-Day Moving Average | 2.85 |
| Relative Strength Index (RSI) | 45.15 |
| Average Volume (20 Days) | 2.00M |
Income Statement
In the last 12 months, Nuvation Bio had revenue of $0 and earned -$75.80M in profits. Earnings per share was $-0.35.
| Revenue | 0 |
| Gross Profit | -222.00K |
| Operating Income | -99.82M |
| Net Income | -75.80M |
| EBITDA | -99.60M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.35 |
Balance Sheet
The company has $42.65M in cash and $4.01M in debt, giving a net cash position of $38.64M.
| Cash & Cash Equivalents | 42.65M |
| Total Debt | 4.01M |
| Net Cash | 38.64M |
| Retained Earnings | -342.80M |
| Total Assets | 571.58M |
| Working Capital | 505.95M |
Cash Flow
In the last 12 months, operating cash flow was -$68.00M and capital expenditures -$69.00K, giving a free cash flow of -$68.07M.
| Operating Cash Flow | -68.00M |
| Capital Expenditures | -69.00K |
| Free Cash Flow | -68.07M |
| FCF Per Share | -0.31 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
NUVB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -13.36% |
| FCF Yield | -7.72% |
Analyst Forecast
The average price target for NUVB is $6, which is 129% higher than the current price. The consensus rating is "Buy".
| Price Target | $6 |
| Price Target Difference | 129% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 3.52 |
| Piotroski F-Score | 2 |